Simple Summary Biliary tract cancers (BTCs) are rare tumours associated with poor
prognosis. In advanced-stage disease, two treatment lines are approved: gemcitabine …

Highlights•CCAs may harbor a range of genetic alterations, some of which are actionable
targets.•It is now recommented to treat patients with IDH1 and FGFR2 alterations with …

Biliary tract cancers (BTCs) represent a spectrum of malignancies associated with a dismal
prognosis. Recent genomic profiling studies have provided a deeper understanding of the …

Simple Summary In oncology, a new era has emerged in the last ten years with the
development of targeted and immune therapies. In hepatocellular carcinoma (HCC), several …

Cholangiocarcinoma (CCA) is a heterogeneous group of neoplasms burdened by a dismal
prognosis. Several studies have investigated the genomic profile of CCA and identified …

Introduction This document is a summary of the French intergroup guidelines of the
management of biliary tract cancers (BTC)(intrahepatic, perihilar and distal …

Cholangiocarcinoma is a group of malignancies with poor prognosis. Treatments for the
management of advanced-stage cholangiocarcinoma are limited, and the 5-year survival …

For advanced cancers of the digestive system, personalized, precise treatment can be life
saving. With the development of next-generation sequencing technology, detection of fusion …

Biliary tract cancer (BTC) is a rare cancer with poor prognosis, characterized by
considerable pathophysiological and molecular heterogeneity. While this makes it difficult to …

Highlights•Review of treatments for biliary tract cancer, especially in the advanced
stage.•Special focus on genetic alterations and advances in immunotherapies until …